CD19 and systemic lupus erythematosus: An investigational trial is being conducted to evaluate the safety, tolerability, initial therapeutic (preliminary efficacy), pharmacokinetic (PK) profile, and pharmacodynamic (PD) responses of CD19-directed chimeric antigen receptor (CAR)-T cell therapy in patients with refractory or moderately to severely active SLE.